Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease Read more about Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies Read more about A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype Read more about Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
First-in-Human Study of ICT01 in Patients With Advanced Cancer Read more about First-in-Human Study of ICT01 in Patients With Advanced Cancer
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS) Read more about A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma Read more about DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer Read more about Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
Use of a Comprehensive, Mobile Application to Assist Cancer Patients With Diet, Nutrition and Activity Read more about Use of a Comprehensive, Mobile Application to Assist Cancer Patients With Diet, Nutrition and Activity
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE Read more about REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy Read more about A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy